The DIABLO Knockout NCI-H1975 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DIABLO gene in the NCI-H1975 human lung adenocarcinoma cell line. This loss-of-function model enables investigation of DIABLO-dependent apoptotic signaling and mitochondrial regulation without introducing defined clonal artifacts. By targeting the endogenous DIABLO locus in a heterogeneous polyclonal pool, researchers can study gene function under near-physiological expression conditions while retaining the oncogenic driver mutations of the parental line.
NCI-H1975 is a well-characterized lung adenocarcinoma epithelial cell line harboring activating EGFR L858R and resistance-associated T790M mutations. Derived from a non-smoker female, it serves as a primary model for studying acquired resistance to first-generation EGFR tyrosine kinase inhibitors and for evaluating next-generation therapeutic strategies. The cellular background faithfully recapitulates key aspects of non-small cell lung cancer (NSCLC) biology, including dysregulated proliferation, apoptotic evasion, and mitochondrial remodeling, making it an appropriate host for investigating DIABLO-mediated cell death regulation.
DIABLO (SMAC) is a pro-apoptotic mitochondrial intermembrane protein released into the cytosol in response to cellular stress. Upon release, it binds and neutralizes Inhibitor of Apoptosis Proteins (IAPs) such as XIAP, cIAP1, and cIAP2, thereby alleviating caspase inhibition and enabling caspase-9, -3, and -7 activation and execution of apoptosis. DIABLO release is regulated by upstream signals including p53, TNF-alpha, and TRAIL, and occurs downstream of mitochondrial outer membrane permeabilization mediated by BAX and BAK. The protein also modulates NF-??B signaling through interactions with cIAPs and forms complexes with Omi/HtrA2 and ARTS, integrating multiple apoptotic inputs.
Disruption of DIABLO in EGFR-mutant NCI-H1975 cells creates a powerful platform to dissect apoptosis resistance mechanisms frequently observed in NSCLC. Since DIABLO is central to both intrinsic and extrinsic apoptotic pathways, its loss-of-function phenotype can unmask dependencies on specific IAP family members or alternative cell death routes. This model is particularly valuable for evaluating the efficacy of SMAC mimetics and other pro-apoptotic compounds in a background where EGFR signaling drives survival, enabling studies of mitochondrial priming and caspase activity thresholds critical for understanding drug-induced cytotoxicity.
Typical research applications include apoptosis mechanism dissection, drug resistance studies, and validation of SMAC mimetic candidates. Compatible assays encompass Annexin V/PI flow cytometry, Western blot for DIABLO and cleaved caspases, caspase activity measurements, co-immunoprecipitation for DIABLO-XIAP complexes, and cell viability assays with mitochondrial membrane potential (JC-1) assessment. The polyclonal population also supports RT-qPCR for knockdown efficiency and immunofluorescence for DIABLO release. For technical inquiries, please contact Ascent Research.
